Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 3/7/2025 | $17.00 | Sector Outperform | Scotiabank |
| 12/11/2024 | Buy → Hold | Needham | |
| 2/26/2024 | $14.00 → $8.00 | Outperform → Neutral | Robert W. Baird |
| 2/8/2024 | $11.00 | Buy | Citigroup |
| 12/11/2023 | $5.00 | Outperform → Neutral | Wedbush |
| 12/8/2023 | $18.00 | Overweight | JP Morgan |
| 4/28/2023 | $20.00 | Outperform | Robert W. Baird |
| 3/27/2023 | $28.00 | Buy | H.C. Wainwright |
SC 13G/A - Cogent Biosciences, Inc. (0001622229) (Subject)
SC 13G/A - Cogent Biosciences, Inc. (0001622229) (Subject)
SC 13G/A - Cogent Biosciences, Inc. (0001622229) (Subject)
WALTHAM, Mass. and BOULDER, Colo., May 23, 2024 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (NASDAQ:COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced the appointment of Cole Pinnow as Chief Commercial Officer. Mr. Pinnow is a leader in the biopharmaceutical industry with an impressive track record in commercial strategy, including several successful product launches. At Cogent, he will be responsible for building and leading the commercial team including sales, marketing, access, and commercial operations. A key priority will be preparing the company for the potential commercial launch of bezuclastinib, for patients
WALTHAM, Mass. and BOULDER, Colo., Nov. 28, 2022 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (NASDAQ:COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced the appointment of Rachael Easton, MD, Ph.D., Vice President, Head of Clinical Development. "We are pleased to welcome Dr. Easton to Cogent as we continue to develop bezuclastinib in Systemic Mastocytosis and GIST," said Andrew Robbins, the company's President and Chief Executive Officer. "Dr. Easton is an accomplished physician-scientist who brings a wealth of experience in both early and late-stage clinical development across multiple therapeutic areas. Her backgrou
CAMBRIDGE, Mass. and BOULDER, Colo., May 3, 2021 /PRNewswire/ -- Cogent Biosciences, Inc. (NASDAQ:COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced the appointment of Evan Kearns as Chief Legal Officer. In his new role, Mr. Kearns will oversee all corporate legal operations for Cogent Biosciences. "I am excited to welcome Evan to the Cogent team as our Chief Legal Officer," said Andrew Robbins, President and Chief Executive Officer of Cogent Biosciences. "Evan's expert counsel and proven leadership in ad
WALTHAM, Mass. and BOULDER, Colo., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (NASDAQ:COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced upcoming presentations for bezuclastinib at the 64th Annual Meeting of the American Society of Hematology (ASH) being held in New Orleans, LA from December 10-13, 2022. The company will also host a virtual investor event on December 12 that will be accessible via conference call and webcast, with full details to be made available closer to the date. Oral presentation details: Preliminary Safety and Efficacy from Apex, a Phase 2 Study of Bezuclastinib (CGT9486), a Nov
All patients treated with bezuclastinib achieved ≥50% reduction in serum tryptase, with a median reduction of 89%, regardless of prior KIT D816V inhibitor treatment All bone marrow biopsy-assessed patients achieved ≥50% bone marrow mast cell reduction and decreases in blood KIT D816V variant allele fraction (VAF) Bezuclastinib demonstrates favorable initial safety and tolerability profile with no reported periorbital or peripheral edema, cognitive effects or intracranial bleeding events Cogent to host investor conference call and webcast today at 8:00 a.m. ET CAMBRIDGE, Mass. and BOULDER, Colo., June 10, 2022 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (NASDAQ:COGT), a biote
Scotiabank initiated coverage of Cogent Biosciences with a rating of Sector Outperform and set a new price target of $17.00
Needham downgraded Cogent Biosciences from Buy to Hold
Robert W. Baird downgraded Cogent Biosciences from Outperform to Neutral and set a new price target of $8.00 from $14.00 previously
4 - Cogent Biosciences, Inc. (0001622229) (Issuer)
4 - Cogent Biosciences, Inc. (0001622229) (Issuer)
4 - Cogent Biosciences, Inc. (0001622229) (Issuer)
Facility provides additional funding for next steps of the Company's growth, including the expected launch of bezuclastinib in 2026 On track to report results from three pivotal trials this year, beginning with SUMMIT results in July WALTHAM, Mass. and BOULDER, Colo., June 11, 2025 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (NASDAQ:COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced it has secured a debt financing facility of up to $400 million with credit funds managed by SLR Capital Partners, LLC ("SLR"). An initial tranche of $50 million was drawn at closing, with future tranches available based on the achieveme
WALTHAM, Mass. and BOULDER, Colo., May 29, 2025 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (NASDAQ:COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced its presentation at the Jefferies Global Healthcare Conference on Thursday, June 5, 2025 at 7:35 a.m. ET. A live webcast will be available on the Investors & Media page of Cogent's website at investors.cogentbio.com. A replay of the webcast will be available approximately two hours after the completion of the event and will be archived for up to 30 days. Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Cogent also announced today that, on May 19, 2025, t
Three Registration-Directed Top-line Data Readouts Remain on Track in 2025: SUMMIT in NonAdvanced SM expected in July, APEX in Advanced SM expected in second half of the-year and PEAK in GIST expected by end of year Ended 1Q 2025 with $245.7 million in cash, sufficient to fund operations into late 2026 WALTHAM, Mass. and BOULDER, Colo., May 06, 2025 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (NASDAQ:COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today provided a business update and announced financial results for the first quarter ended March 31, 2025. "The first quarter of 2025 was very productive for Cogent
4 - Cogent Biosciences, Inc. (0001622229) (Issuer)
8-K - Cogent Biosciences, Inc. (0001622229) (Filer)
8-K - Cogent Biosciences, Inc. (0001622229) (Filer)
EFFECT - Cogent Biosciences, Inc. (0001622229) (Filer)